Stem Cell Therapy Boosts Quality of Life for People With Advanced Heart Failure
FRIDAY, Dec. 15, 2023 -- Patients with advanced heart failure can benefit from stem cell therapy, a large, new clinical trial has found.
Injections of stem cells programmed to heal damaged heart tissue wound up improving overall quality of life for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 15, 2023 Category: General Medicine Source Type: news
Why Some Myeloma Patients Refuse Stem Cell Transplant
(MedPage Today) -- A real-world analysis presented at the American Society of Hematology annual meeting showed that the refusal rate for autologous hematopoietic stem cell transplantation among patients with multiple myeloma is low, at about 2... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 15, 2023 Category: Hematology Source Type: news
News at a glance: AI rules for Europe, vaccines for Africa, and a union for NIH early-career researchers
HEALTH EQUITY
A billion-dollar boost for vaccinemaking in Africa
Gavi, the Vaccine Alliance, has committed up to $1 billion to bolster Africa’s ability to sustainably produce its own doses of lifesaving vaccines. Manufacturers based in Africa produce only 1% of the vaccine doses used on the continent. Last week, Gavi announced that with money left over from the COVID-19 Vaccines Global Access Facility—an effort to provide an equitable distribution of COVID-19 vaccines—it would create the African Vaccine Manufacturing Accelerator (AVMA) to focus on preventing 11 priority infectious diseases. As ...
Source: ScienceNOW - December 14, 2023 Category: Science Source Type: news
'Half-Matched' BMTs Effective in Severe Sickle Cell Disease
(MedPage Today) -- SAN DIEGO -- A reduced-intensity "half-matched" bone marrow transplant (BMT) protocol demonstrated durable donor engraftment, with encouraging survival rates, in adults with severe sickle cell disease (SCD) for whom stem cell... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 13, 2023 Category: Hematology Source Type: news
Stem Cell Therapy Implant Shows Promise for Type 1 Diabetes Stem Cell Therapy Implant Shows Promise for Type 1 Diabetes
An experimental device containing millions of stem cells significantly reduced the need for insulin shots among people with type 1 diabetes.WebMD Health News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 12, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology Source Type: news
Companies Market Stem Cell Treatments to Long COVID Patients
(MedPage Today) -- Clinics that sell stem cell and exosome treatments have turned their attention to long COVID patients, researchers found.
Among 38 businesses selling such treatments for COVID-19, the majority (36) marketed those therapies for... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 12, 2023 Category: American Health Source Type: news
Clinical trial finds cell therapy improves quality of life in advanced heart failure
ROCHESTER, Minn. — Stem cell-based therapy improved quality of life for patients with advanced heart failure, Mayo Clinic researchers and international collaborators discovered in a late-stage multinational clinical trial. In one of the largest studies of cell intervention after a heart attack, patients reported t heir daily hardship lessened when stem cells optimized for heart repair supplemented standard of care. This clinical study further documented lower death and hospitalization rates among those treated with cell therapy.… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 12, 2023 Category: Databases & Libraries Source Type: news
Stem Cell Therapy Implant Shows Promise For Type 1 Diabetes
Researchers say the treatment may someday provide a cure for the chronic, life-altering condition. (Source: WebMD Health)
Source: WebMD Health - December 11, 2023 Category: Consumer Health News Source Type: news
New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Media News - December 11, 2023 Category: Pharmaceuticals Source Type: news
New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Investor Update - December 11, 2023 Category: Pharmaceuticals Source Type: news
Could the ‘central dogma’ of biology be misleading bioengineers?
Key takeawaysMesenchymal stem cells, found in bone marrow, secrete therapeutic proteins that could potentially help regenerate damaged tissue.A UCLA study examining these cells challenges the conventional understanding of which genetic instructions prompt the release of these therapeutic proteins.The findings could help advance both regenerative medicine research and the laboratory production of biologic treatments already in use.Today, medicines based on antibodies— proteins that fight infection and disease —are prescribed for everything from cancer to COVID-19 to high cholesterol.The antibody drugs are supplied by ...
Source: UCLA Newsroom: Health Sciences - December 11, 2023 Category: Universities & Medical Training Source Type: news
ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission
(MedPage Today) -- SAN DIEGO -- Autologous stem-cell transplantation (ASCT) led to improved outcomes as compared with CAR T-cell therapy for patients with relapsed large B-cell lymphoma (LBCL) in complete remission, a retrospective analysis showed... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 11, 2023 Category: Hematology Source Type: news
New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most
There is no clear path for African patients to get access to the treatments, which have multimillion-dollar price tags and are highly complex to manufacture and deliver. (Source: NYT Health)
Source: NYT Health - December 8, 2023 Category: Consumer Health News Authors: Rebecca Robbins and Stephanie Nolen Tags: Sickle Cell Anemia Genetic Engineering Blood Genetics and Heredity Income Inequality Bone Marrow Drugs (Pharmaceuticals) Therapy and Rehabilitation Developing Countries Crispr (DNA) Transplants Stem Cells Food and Drug Administrati Source Type: news
US regulators approve two gene therapies for sickle cell disease
Blood disorder that can lead to premature death affects estimated 100,000 people in the United States, most of whom are BlackThe US Food and Drug Administration has approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough Crispr gene-editing technology, opening up two “transformative therapy” avenues for some patients.The FDA approved Lyfgenia from Bluebird Bio, and a separate treatment called Casgevy by partners Vertex Pharmaceuticals and Crispr Therapeutics. Both therapies are made from the patients ’ own blood stem cells and were approved for people aged 12...
Source: Guardian Unlimited Science - December 8, 2023 Category: Science Authors: Edward Helmore and agencies Tags: US news Health World news Society Medicine Gene editing Science Source Type: news
FDA Approves First CRISPR Treatment in U.S.
It was only 11 years ago that scientists Jennifer Doudna and Emmanuelle Charpentier first described a new way to edit genes, called CRISPR, in a scientific paper. The discovery is so game-changing that the pair earned the Nobel Prize in Chemistry in 2020 for how it could transform the way genetic diseases are treated. Now, on Dec. 8, the U.S. Food and Drug Administration (FDA) approved the very first treatment in the country based on the technology.
[time-brightcove not-tgx=”true”]
In the medical world, that’s lightning speed. “It’s incredible,” says Doudna, professor of chemistry a...
Source: TIME: Health - December 8, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Source Type: news
